SynthesisExperimental brain research2025
The synergistic effects of cycloserine and anodal tDCS: a systematic review and meta-analysis.
Synthesis in Experimental brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Opioid- and NMDA-receptor-dependent neural plasticity mediates long-term analgesia from motor cortical stimulation.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review examines the synergistic effects of Cycloserine and anodal transcranial direct current stimulation (tDCS) on cortical excitability and clinical outcomes. tDCS, a non-invasive neuromodulation technique, modulates cortical excitability, potentially enhancing neuroplasticity. Cycloserine, a partial agonist at NMDA receptors, may potentiate tDCS effects by stabilizing receptor activity. A comprehensive database search identified five eligible studies focusing on healthy participants, with one involving patients with depression. Meta-analysis revealed that Cycloserine prolonged cortical excitability 60 min post-tDCS (SMD: 0.66, 95% CI: 0.05 to 1.27), with the greatest effect observed at a 100 mg dosage (SMD: 0.78, 95% CI: 0.26 to 1.31). Although this suggests a potential enhancement of tDCS efficacy, clinical improvements, such as in depression or motor learning, were not consistently significant across studies. Overall, while Cycloserine appears to extend tDCS-induced cortical excitability, more robust clinical trials are necessary to confirm its therapeutic benefits.
Indexed as
Identifiers
40100389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.